# Cysteinyl Leukotriene Antagonist in Atherosclerosis Inhibition in Patients After Endovascular Treatment Due to Peripheral Arterial Disease

> **NCT04277702** · PHASE3 · UNKNOWN · sponsor: **Jagiellonian University** · enrollment: 200 (estimated)

## Conditions studied

- Peripheral Arterial Disease
- Peripheral Vascular Diseases
- Lower Limb Ischemia
- Atherosclerosis of Artery

## Interventions

- **DRUG:** Montelukast 10mg
- **PROCEDURE:** Endovascular treatment
- **DRUG:** Standard anti-platelet treatment

## Key facts

- **NCT ID:** NCT04277702
- **Lead sponsor:** Jagiellonian University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-05
- **Primary completion:** 2023-10
- **Final completion:** 2023-12
- **Target enrollment:** 200 (ESTIMATED)
- **Last updated:** 2020-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04277702

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04277702, "Cysteinyl Leukotriene Antagonist in Atherosclerosis Inhibition in Patients After Endovascular Treatment Due to Peripheral Arterial Disease". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT04277702. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*